We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTOO
101
DELISTED
T2 Biosystems, Inc
TTOO
$649K 0.01%
20
– –
AKTX
102
Akari Therapeutics
AKTX
$15.3M
$618K 0.01%
425
-446
-51% -$963K
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$579K ﹤0.01%
4,827
– –
FLGT icon
104
Fulgent Genetics
FLGT
$548M
$500K ﹤0.01%
125,000
– –
IMDZ
105
DELISTED
Immune Design Corp.
IMDZ
$491K ﹤0.01%
148,937
– –
BDSI
106
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$473K ﹤0.01%
210,021
– –
BGMSP
107
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$77K ﹤0.01%
13,253
– –
BTX.WS
108
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$2K ﹤0.01%
20,084
– –
AGIO icon
109
Agios Pharmaceuticals
AGIO
$1.98B
– –
-128,666
Closed -$7.36M
KPTI icon
110
Karyopharm Therapeutics
KPTI
$44.5M
– –
-14,466
Closed -$2.08M
LGND icon
111
Ligand Pharmaceuticals
LGND
$5.71B
– –
-117,638
Closed -$10M
TENX icon
112
Tenax Therapeutics
TENX
$65.5M
– –
-11
Closed -$171K
ITCI
113
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-609,166
Closed -$8.82M
IMGN
114
DELISTED
Immunogen Inc
IMGN
– –
-2,563,489
Closed -$16.4M
ACOR
115
DELISTED
Acorda Therapeutics
ACOR
– –
-1,716
Closed -$4.42M
EPZM
116
DELISTED
Epizyme, Inc
EPZM
– –
-232,481
Closed -$2.92M
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-19,247
Closed -$422K
AKAO
118
DELISTED
Achaogen Inc
AKAO
– –
-122,482
Closed -$1.31M
NVIV
119
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-18
Closed -$255K
AAAP
120
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-55,125
Closed -$4.5M
RXDX
121
DELISTED
Ignyta, Inc.
RXDX
– –
-1,384,266
Closed -$37M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2018 Portfolio in Review

As of Q1 2018, Julian Baker held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Julian Baker deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was Yarrow Bioscience: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Julian Baker's largest Q1 2018 buy was Yarrow Bioscience: 194 shares worth $26.3M.
  • Julian Baker added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Julian Baker's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Julian Baker fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Julian Baker's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Julian Baker opened 5 new positions and closed 13 in Q1 2018.
  • Julian Baker's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.